New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Amicus Therapeutics, Inc.
FOLD
Shape
US Flag

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

3B

Biotechnology

Next Earning date - 13 Nov 2024

3B

Biotechnology

Next Earning date - 13 Nov 2024

11.69USD
Shape-0.07 ( -0.60%)
favorite-chart

Relative Strenght

17
favorite-chart

Volume Buzz

-29%
favorite-chart

Earning Acce

Yes
favorite-chart

Dist 52w H.

20%

Quote Panel

Shape
Updated October 27, 2024
1W -2.66 % 1M 9.46 % 3M 15.63 % 1Y 7.05 %

Key Metrics

Shape
  • Market Cap

    3.47B


  • Shares Outstanding

    296.59M


  • Share in Float

    289.03M


  • Dividende

    0


  • Earning Date

    13 Nov 2024


  • Price Target

    11.69


  • Average Volume

    2.59M


  • Beta

    0.684


  • Range

    9.02-14.57


  • Industry

    Biotechnology


  • Website

    https://amicusrx.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

7.61x

P/S Ratio

26.80x

P/B Ratio

3.0

Debt/Equity

-26.2%

Net Margin

$-0.4

EPS

How FOLD compares to sector?

P/E Ratio

Relative Strength

Shape

FOLD

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$641M

Shape406%

2025-Revenue

$0.18

Shape445%

2025-EPS

$420M

Shape-2551%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Jefferies

initialise

Previous: Not converted

2024-09-06

Now: Buy

Wells Fargo

initialise

Previous: Not converted

2024-05-30

Now: Overweight

Guggenheim

upgrade

Previous: Not converted

2024-05-14

Now: Buy

Morgan Stanley

upgrade

Previous: Not converted

2023-12-19

Now: Overweight

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-0.12
vs -0.19

Q4.22

arrow
arrow

N/A

-0.19
vs -0.29

Q1.23

arrow
arrow

N/A

-0.18
vs -0.30

Q2.23

arrow
arrow

N/A

-0.15
vs -0.21

Q3.23

arrow
arrow

N/A

-0.07
vs -0.12

Q4.23

arrow
arrow

N/A

-0.11
vs -0.19

Q1.24

arrow
arrow

N/A

-0.02
vs -0.18

Q2.24

arrow
arrow

+140%

0.06
vs -0.15

Q3.24

arrow
arrow

+102%

0
vs -0.07

Q4.24

arrow
arrow

+112%

0.01
vs -0.11

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

+3%

81.7M  vs 79.5M

Q4.22

arrow
arrow

+7%

88.1M  vs 82.2M

Q1.23

arrow
arrow

+10%

86.3M  vs 78.7M

Q2.23

arrow
arrow

+17%

94.5M  vs 80.7M

Q3.23

arrow
arrow

+27%

103.5M  vs 81.7M

Q4.23

arrow
arrow

+31%

115.1M  vs 88.1M

Q1.24

arrow
arrow

+28%

110.4M  vs 86.3M

Q2.24

arrow
arrow

+34%

126.7M  vs 94.5M

Q3.24

arrow
arrow

+30%

134.9M  vs 103.5M

Q4.24

arrow
arrow

+26%

145.5M  vs 115.1M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-25%

-0.25
vs -0.36

Q4.22

arrow
arrow

-45%

-0.45
vs -0.25

Q1.23

arrow
arrow

-52%

-0.52
vs -0.45

Q2.23

arrow
arrow

-39%

-0.39
vs -0.52

Q3.23

arrow
arrow

-16%

-0.16
vs -0.39

Q4.23

arrow
arrow

-21%

-0.21
vs -0.16

Q1.24

arrow
arrow

-37%

-0.37
vs -0.21

Q2.24

arrow
arrow

-12%

-0.12
vs -0.37

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

233

233
vs 221

5%

Q4.22

arrow
arrow

241

241
vs 233

3%

Q1.23

arrow
arrow

231

231
vs 241

-4%

Q2.23

arrow
arrow

226

226
vs 231

-2%

Q3.23

arrow
arrow

244

244
vs 226

8%

Q4.23

arrow
arrow

243

243
vs 244

0%

Q1.24

arrow
arrow

262

262
vs 243

8%

Q2.24

arrow
arrow

266

266
vs 262

2%

Earnings Growth

Latest News